



Global Primary Hyperoxaluria Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-26	184	PDF

Single User	Multi User	Enterprise
USD 3,950	USD 5,925	USD 7,900

Description

The global Primary Hyperoxaluria Drug market is projected to grow from US\$ million in 2026 to US\$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Primary Hyperoxaluria Drug is projected to increase from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Primary Hyperoxaluria Drug is projected to increase from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026-2032.

The Asia Pacific market for Primary Hyperoxaluria Drug is projected to increase from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Primary Hyperoxaluria Drug is projected to increase from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Primary Hyperoxaluria Drug include OxThera AB, Intellia Therapeutics Inc, Dicerna Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc and Allena Pharmaceuticals Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Primary Hyperoxaluria Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Primary Hyperoxaluria Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Primary Hyperoxaluria Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Primary Hyperoxaluria Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Primary Hyperoxaluria Drug Segment by Company

- OxThera AB
- Intellia Therapeutics Inc
- Dicerna Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Allena Pharmaceuticals Inc

Primary Hyperoxaluria Drug Segment by Type

ALLN-230

ALN-GO1

DCR-PHXC

Others

Primary Hyperoxaluria Drug Segment by Application

Hospital

Clinic

Others

Primary Hyperoxaluria Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Primary Hyperoxaluria Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Primary Hyperoxaluria Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Primary Hyperoxaluria Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Provides an overview of the Primary Hyperoxaluria Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2:

Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3:

Detailed analysis of Primary Hyperoxaluria Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4:

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5:

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6:

Sales of Primary Hyperoxaluria Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7:

Revenue of Primary Hyperoxaluria Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9:

Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10:

Concluding Insights of the report

Table of Contents

1 Market Overview

- 1.1 Product Definition
- 1.2 Global Primary Hyperoxaluria Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Primary Hyperoxaluria Drug Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Primary Hyperoxaluria Drug Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Primary Hyperoxaluria Drug Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives

2 Global Primary Hyperoxaluria Drug Market Dynamics

- 2.1 Primary Hyperoxaluria Drug Industry Trends
- 2.2 Primary Hyperoxaluria Drug Industry Drivers
- 2.3 Primary Hyperoxaluria Drug Industry Opportunities and Challenges
- 2.4 Primary Hyperoxaluria Drug Industry Restraints

3 Primary Hyperoxaluria Drug Market by Manufacturers

- 3.1 Global Primary Hyperoxaluria Drug Revenue by Manufacturers (2021-2026)
- 3.2 Global Primary Hyperoxaluria Drug Sales by Manufacturers (2021-2026)
- 3.3 Global Primary Hyperoxaluria Drug Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Primary Hyperoxaluria Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Primary Hyperoxaluria Drug Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Primary Hyperoxaluria Drug Manufacturers, Product Type & Application
- 3.7 Global Primary Hyperoxaluria Drug Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
 - 3.8.1 Global Primary Hyperoxaluria Drug Market CR5 and HHI
 - 3.8.2 Global Top 5 and 10 Primary Hyperoxaluria Drug Players Market Share by Revenue in 2025
 - 3.8.3 2025 Primary Hyperoxaluria Drug Tier 1, Tier 2, and Tier 3

4 Primary Hyperoxaluria Drug Market by Type

- 4.1 Primary Hyperoxaluria Drug Type Introduction
 - 4.1.1 ALLN-230
 - 4.1.2 ALN-GO1
 - 4.1.3 DCR-PHXC
 - 4.1.4 Others
- 4.2 Global Primary Hyperoxaluria Drug Sales by Type
 - 4.2.1 Global Primary Hyperoxaluria Drug Sales by Type (2021 VS 2025 VS 2032)
 - 4.2.2 Global Primary Hyperoxaluria Drug Sales by Type (2021-2032)
 - 4.2.3 Global Primary Hyperoxaluria Drug Sales Market Share by Type (2021-2032)
- 4.3 Global Primary Hyperoxaluria Drug Revenue by Type
 - 4.3.1 Global Primary Hyperoxaluria Drug Revenue by Type (2021 VS 2025 VS 2032)
 - 4.3.2 Global Primary Hyperoxaluria Drug Revenue by Type (2021-2032)
 - 4.3.3 Global Primary Hyperoxaluria Drug Revenue Market Share by Type (2021-2032)

5 Primary Hyperoxaluria Drug Market by Application

- 5.1 Primary Hyperoxaluria Drug Application Introduction
 - 5.1.1 Hospital

5.1.2 Clinic

5.1.3 Others

5.2 Global Primary Hyperoxaluria Drug Sales by Application

5.2.1 Global Primary Hyperoxaluria Drug Sales by Application (2021 VS 2025 VS 2032)

5.2.2 Global Primary Hyperoxaluria Drug Sales by Application (2021-2032)

5.2.3 Global Primary Hyperoxaluria Drug Sales Market Share by Application (2021-2032)

5.3 Global Primary Hyperoxaluria Drug Revenue by Application

5.3.1 Global Primary Hyperoxaluria Drug Revenue by Application (2021 VS 2025 VS 2032)

5.3.2 Global Primary Hyperoxaluria Drug Revenue by Application (2021-2032)

5.3.3 Global Primary Hyperoxaluria Drug Revenue Market Share by Application (2021-2032)

6 Global Primary Hyperoxaluria Drug Sales by Region

6.1 Global Primary Hyperoxaluria Drug Sales by Region: 2021 VS 2025 VS 2032

6.2 Global Primary Hyperoxaluria Drug Sales by Region (2021-2032)

6.2.1 Global Primary Hyperoxaluria Drug Sales by Region (2021-2026)

6.2.2 Global Primary Hyperoxaluria Drug Sales Forecasted by Region (2027-2032)

6.3 North America

6.3.1 North America Primary Hyperoxaluria Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032

6.3.2 North America Primary Hyperoxaluria Drug Sales by Country (2021-2032)

6.3.3 U.S.

6.3.4 Canada

6.3.5 Mexico

6.4 Europe

6.4.1 Europe Primary Hyperoxaluria Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032

6.4.2 Europe Primary Hyperoxaluria Drug Sales by Country (2021-2032)

6.4.3 Germany

6.4.4 France

6.4.5 U.K.

6.4.6 Italy

6.4.7 Netherlands

6.5 Asia Pacific

6.5.1 Asia Pacific Primary Hyperoxaluria Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032

6.5.2 Asia Pacific Primary Hyperoxaluria Drug Sales by Country (2021-2032)

6.5.3 China

6.5.4 Japan

6.5.5 South Korea

6.5.6 Southeast Asia

6.5.7 India

6.5.8 Australia

6.6 South America, Middle East and Africa

6.6.1 South America, Middle East and Africa Primary Hyperoxaluria Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032

6.6.2 South America, Middle East and Africa Primary Hyperoxaluria Drug Sales by Country (2021-2032)

6.6.3 Brazil

6.6.4 South Africa

6.6.5 Saudi Arabia

6.6.6 Turkey

6.6.6 Argentina

6.6.6 UAE

- 6.6.6 Egypt
- 6.6.6 Chile

7 Global Primary Hyperoxaluria Drug Revenue by Region

- 7.1 Global Primary Hyperoxaluria Drug Revenue by Region
 - 7.1.1 Global Primary Hyperoxaluria Drug Revenue by Region: 2021 VS 2025 VS 2032
 - 7.1.2 Global Primary Hyperoxaluria Drug Revenue by Region (2021-2026)
 - 7.1.3 Global Primary Hyperoxaluria Drug Revenue by Region (2027-2032)
 - 7.1.4 Global Primary Hyperoxaluria Drug Revenue Market Share by Region (2021-2032)
- 7.2 North America
 - 7.2.1 North America Primary Hyperoxaluria Drug Revenue (2021-2032)
 - 7.2.2 North America Primary Hyperoxaluria Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
 - 7.3.1 Europe Primary Hyperoxaluria Drug Revenue (2021-2032)
 - 7.3.2 Europe Primary Hyperoxaluria Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
 - 7.4.1 Asia-Pacific Primary Hyperoxaluria Drug Revenue (2021-2032)
 - 7.4.2 Asia-Pacific Primary Hyperoxaluria Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
 - 7.5.1 South America, Middle East and Africa Primary Hyperoxaluria Drug Revenue (2021-2032)
 - 7.5.2 South America, Middle East and Africa Primary Hyperoxaluria Drug Revenue Share by Country: 2021 VS 2025 VS 2032

8 Company Profiles

- 8.1 OxThera AB
 - 8.1.1 OxThera AB Company Information
 - 8.1.2 OxThera AB Business Overview
 - 8.1.3 OxThera AB Primary Hyperoxaluria Drug Sales, Price, Revenue and Gross Margin (2021-2026)
 - 8.1.4 OxThera AB Primary Hyperoxaluria Drug Product Portfolio
 - 8.1.5 OxThera AB Recent Developments
- 8.2 Intellia Therapeutics Inc
 - 8.2.1 Intellia Therapeutics Inc Company Information
 - 8.2.2 Intellia Therapeutics Inc Business Overview
 - 8.2.3 Intellia Therapeutics Inc Primary Hyperoxaluria Drug Sales, Price, Revenue and Gross Margin (2021-2026)
 - 8.2.4 Intellia Therapeutics Inc Primary Hyperoxaluria Drug Product Portfolio
 - 8.2.5 Intellia Therapeutics Inc Recent Developments
- 8.3 Dicerna Pharmaceuticals Inc
 - 8.3.1 Dicerna Pharmaceuticals Inc Company Information
 - 8.3.2 Dicerna Pharmaceuticals Inc Business Overview
 - 8.3.3 Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales, Price, Revenue and Gross Margin (2021-2026)
 - 8.3.4 Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio
 - 8.3.5 Dicerna Pharmaceuticals Inc Recent Developments
- 8.4 Alnylam Pharmaceuticals Inc
 - 8.4.1 Alnylam Pharmaceuticals Inc Company Information
 - 8.4.2 Alnylam Pharmaceuticals Inc Business Overview
 - 8.4.3 Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales, Price, Revenue and Gross Margin (2021-2026)
 - 8.4.4 Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio
 - 8.4.5 Alnylam Pharmaceuticals Inc Recent Developments
- 8.5 Allena Pharmaceuticals Inc

- 8.5.1 Allena Pharmaceuticals Inc Company Information
- 8.5.2 Allena Pharmaceuticals Inc Business Overview
- 8.5.3 Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio
- 8.5.5 Allena Pharmaceuticals Inc Recent Developments

9 Value Chain and Sales Channels Analysis

- 9.1 Primary Hyperoxaluria Drug Value Chain Analysis
 - 9.1.1 Primary Hyperoxaluria Drug Key Raw Materials
 - 9.1.2 Raw Materials Key Suppliers
 - 9.1.3 Manufacturing Cost Structure
 - 9.1.4 Primary Hyperoxaluria Drug Production Mode & Process
- 9.2 Primary Hyperoxaluria Drug Sales Channels Analysis
 - 9.2.1 Direct Comparison with Distribution Share
 - 9.2.2 Primary Hyperoxaluria Drug Distributors
 - 9.2.3 Primary Hyperoxaluria Drug Customers

10 Concluding Insights

11 Appendix

- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
 - 11.5.1 Secondary Sources
 - 11.5.2 Primary Sources
- 11.6 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Primary Hyperoxaluria Drug Industry Trends
- Table 2: Primary Hyperoxaluria Drug Industry Drivers
- Table 3: Primary Hyperoxaluria Drug Industry Opportunities and Challenges
- Table 4: Primary Hyperoxaluria Drug Industry Restraints
- Table 5: Global Primary Hyperoxaluria Drug Revenue by Manufacturers (US\$ Million) & (2021-2026)
- Table 6: Global Primary Hyperoxaluria Drug Revenue Market Share by Manufacturers (2021-2026)
- Table 7: Global Primary Hyperoxaluria Drug Sales by Manufacturers (W Units) & (2021-2026)
- Table 8: Global Primary Hyperoxaluria Drug Sales Market Share by Manufacturers
- Table 9: Global Primary Hyperoxaluria Drug Average Sales Price (US\$/Unit) of Manufacturers (2021-2026)
- Table 10: Global Primary Hyperoxaluria Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- Table 11: Global Primary Hyperoxaluria Drug Key Manufacturers Manufacturing Sites & Headquarters
- Table 12: Global Primary Hyperoxaluria Drug Manufacturers, Product Type & Application
- Table 13: Global Primary Hyperoxaluria Drug Manufacturers Establishment Date
- Table 14: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 15: Global Primary Hyperoxaluria Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025)
- Table 16: Major Manufacturers of ALLN-230
- Table 17: Major Manufacturers of ALN-GO1
- Table 18: Major Manufacturers of DCR-PHXC
- Table 19: Major Manufacturers of Others
- Table 20: Global Primary Hyperoxaluria Drug Sales by Type 2021 VS 2025 VS 2032 (W Units)
- Table 21: Global Primary Hyperoxaluria Drug Sales by Type (2021-2026) & (W Units)
- Table 22: Global Primary Hyperoxaluria Drug Sales by Type (2027-2032) & (W Units)
- Table 23: Global Primary Hyperoxaluria Drug Sales Market Share by Type (2021-2026)
- Table 24: Global Primary Hyperoxaluria Drug Sales Market Share by Type (2027-2032)
- Table 25: Global Primary Hyperoxaluria Drug Revenue by Type 2021 VS 2025 VS 2032 (W Units)
- Table 26: Global Primary Hyperoxaluria Drug Revenue by Type (2021-2026) & (W Units)
- Table 27: Global Primary Hyperoxaluria Drug Revenue by Type (2027-2032) & (W Units)
- Table 28: Global Primary Hyperoxaluria Drug Revenue Market Share by Type (2021-2026)
- Table 29: Global Primary Hyperoxaluria Drug Revenue Market Share by Type (2027-2032)
- Table 30: Major Manufacturers of Hospital
- Table 31: Major Manufacturers of Clinic
- Table 32: Major Manufacturers of Others
- Table 33: Global Primary Hyperoxaluria Drug Sales by Application 2021 VS 2025 VS 2032 (W Units)
- Table 34: Global Primary Hyperoxaluria Drug Sales by Application (2021-2026) & (W Units)
- Table 35: Global Primary Hyperoxaluria Drug Sales by Application (2027-2032) & (W Units)
- Table 36: Global Primary Hyperoxaluria Drug Sales Market Share by Application (2021-2026)
- Table 37: Global Primary Hyperoxaluria Drug Sales Market Share by Application (2027-2032)
- Table 38: Global Primary Hyperoxaluria Drug Revenue by Application 2021 VS 2025 VS 2032 (W Units)
- Table 39: Global Primary Hyperoxaluria Drug Revenue by Application (2021-2026) & (W Units)
- Table 40: Global Primary Hyperoxaluria Drug Revenue by Application (2027-2032) & (W Units)
- Table 41: Global Primary Hyperoxaluria Drug Revenue Market Share by Application (2021-2026)
- Table 42: Global Primary Hyperoxaluria Drug Revenue Market Share by Application (2027-2032)
- Table 43: Global Primary Hyperoxaluria Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units)
- Table 44: Global Primary Hyperoxaluria Drug Sales by Region (2021-2026) & (W Units)
- Table 45: Global Primary Hyperoxaluria Drug Sales Market Share by Region (2021-2026)
- Table 46: Global Primary Hyperoxaluria Drug Sales Forecasted by Region (2027-2032) & (W Units)
- Table 47: Global Primary Hyperoxaluria Drug Sales Forecasted Market Share by Region (2027-2032)
- Table 48: North America Primary Hyperoxaluria Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units)
- Table 49: North America Primary Hyperoxaluria Drug Sales by Country (2021-2026) & (W Units)
- Table 50: North America Primary Hyperoxaluria Drug Sales by Country (2027-2032) & (W Units)
- Table 51: Europe Primary Hyperoxaluria Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units)
- Table 52: Europe Primary Hyperoxaluria Drug Sales by Country (2021-2026) & (W Units)
- Table 53: Europe Primary Hyperoxaluria Drug Sales by Country (2027-2032) & (W Units)
- Table 54: Asia Pacific Primary Hyperoxaluria Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units)

- Table 55: Asia Pacific Primary Hyperoxaluria Drug Sales by Country (2021-2026) & (W Units)
- Table 56: Asia Pacific Primary Hyperoxaluria Drug Sales by Country (2027-2032) & (W Units)
- Table 57: South America, Middle East and Africa Primary Hyperoxaluria Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units)
- Table 58: South America, Middle East and Africa Primary Hyperoxaluria Drug Sales by Country (2021-2026) & (W Units)
- Table 59: South America, Middle East and Africa Primary Hyperoxaluria Drug Sales by Country (2027-2032) & (W Units)
- Table 60: Global Primary Hyperoxaluria Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 61: Global Primary Hyperoxaluria Drug Revenue by Region (2021-2026) & (US\$ Million)
- Table 62: Global Primary Hyperoxaluria Drug Revenue by Region (2027-2032) & (US\$ Million)
- Table 63: Global Primary Hyperoxaluria Drug Revenue Market Share by Region (2021-2026)
- Table 64: Global Primary Hyperoxaluria Drug Revenue Market Share by Region (2027-2032)
- Table 65: OxThera AB Company Information
- Table 66: OxThera AB Business Overview
- Table 67: OxThera AB Primary Hyperoxaluria Drug Sales (W Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 68: OxThera AB Primary Hyperoxaluria Drug Product Portfolio
- Table 69: OxThera AB Recent Development
- Table 70: Intellia Therapeutics Inc Company Information
- Table 71: Intellia Therapeutics Inc Business Overview
- Table 72: Intellia Therapeutics Inc Primary Hyperoxaluria Drug Sales (W Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 73: Intellia Therapeutics Inc Primary Hyperoxaluria Drug Product Portfolio
- Table 74: Intellia Therapeutics Inc Recent Development
- Table 75: Dicerna Pharmaceuticals Inc Company Information
- Table 76: Dicerna Pharmaceuticals Inc Business Overview
- Table 77: Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales (W Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 78: Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio
- Table 79: Dicerna Pharmaceuticals Inc Recent Development
- Table 80: Alnylam Pharmaceuticals Inc Company Information
- Table 81: Alnylam Pharmaceuticals Inc Business Overview
- Table 82: Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales (W Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 83: Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio
- Table 84: Alnylam Pharmaceuticals Inc Recent Development
- Table 85: Allena Pharmaceuticals Inc Company Information
- Table 86: Allena Pharmaceuticals Inc Business Overview
- Table 87: Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales (W Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 88: Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio
- Table 89: Allena Pharmaceuticals Inc Recent Development
- Table 90: Key Raw Materials
- Table 91: Raw Materials Key Suppliers
- Table 92: Primary Hyperoxaluria Drug Distributors List
- Table 93: Primary Hyperoxaluria Drug Customers List
- Table 94: Research Programs/Design for This Report
- Table 95: Authors List of This Report
- Table 96: Secondary Sources
- Table 97: Primary Sources

List of Figures:

- Figure 1: Primary Hyperoxaluria Drug Product Image
- Figure 2: Global Primary Hyperoxaluria Drug Market Size (US\$ Million), 2021 VS 2025 VS 2032
- Figure 3: Global Primary Hyperoxaluria Drug Market Size (2021-2032) & (US\$ Million)
- Figure 4: Global Primary Hyperoxaluria Drug Sales (2021-2032) & (W Units)
- Figure 5: Global Primary Hyperoxaluria Drug Average Price (US\$/Unit) & (2021-2032)
- Figure 6: Global Top 5 and 10 Primary Hyperoxaluria Drug Players Market Share by Revenue in 2025
- Figure 7: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 8: ALLN-230 Image
- Figure 9: ALN-GO1 Image
- Figure 10: DCR-PHXC Image
- Figure 11: Others Image
- Figure 12: Global Primary Hyperoxaluria Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units)

- Figure 13: Global Primary Hyperoxaluria Drug Sales Market Share 2021 VS 2025 VS 2032
- Figure 14: Global Primary Hyperoxaluria Drug Sales Market Share by Type (2021-2032)
- Figure 15: Global Primary Hyperoxaluria Drug Revenue by Type (2021 VS 2025 VS 2032) & (W Units)
- Figure 16: Global Primary Hyperoxaluria Drug Revenue Market Share 2021 VS 2025 VS 2032
- Figure 17: Global Primary Hyperoxaluria Drug Revenue Market Share by Type (2021-2032)
- Figure 18: Hospital Image
- Figure 19: Clinic Image
- Figure 20: Others Image
- Figure 21: Global Primary Hyperoxaluria Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units)
- Figure 22: Global Primary Hyperoxaluria Drug Sales Market Share 2021 VS 2025 VS 2032
- Figure 23: Global Primary Hyperoxaluria Drug Sales Market Share by Application (2021-2032)
- Figure 24: Global Primary Hyperoxaluria Drug Revenue by Application (2021 VS 2025 VS 2032) & (W Units)
- Figure 25: Global Primary Hyperoxaluria Drug Revenue Market Share 2021 VS 2025 VS 2032
- Figure 26: Global Primary Hyperoxaluria Drug Revenue Market Share by Application (2021-2032)
- Figure 27: North America Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 28: North America Primary Hyperoxaluria Drug Sales Market Share by Country (2021-2032)
- Figure 29: U.S. Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 30: Canada Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 31: Mexico Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 32: Europe Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 33: Europe Primary Hyperoxaluria Drug Sales Market Share by Country (2021-2032)
- Figure 34: Germany Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 35: France Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 36: U.K. Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 37: Italy Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 38: Netherlands Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 39: Asia Pacific Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 40: Asia Pacific Primary Hyperoxaluria Drug Sales Market Share by Country (2021-2032)
- Figure 41: China Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 42: Japan Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 43: South Korea Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 44: Southeast Asia Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 45: India Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 46: Australia Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 47: South America, Middle East and Africa Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 48: South America, Middle East and Africa Primary Hyperoxaluria Drug Sales Market Share by Country (2021-2032)
- Figure 49: Brazil Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 50: South Africa Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 51: Saudi Arabia Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 52: Turkey Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 53: Argentina Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 54: UAE Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 55: Egypt Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 56: Chile Primary Hyperoxaluria Drug Sales and Growth Rate (2021-2032) & (W Units)
- Figure 57: Global Primary Hyperoxaluria Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US\$ Million)
- Figure 58: Global Primary Hyperoxaluria Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032
- Figure 59: North America Primary Hyperoxaluria Drug Revenue (2021-2032) & (US\$ Million)
- Figure 60: North America Primary Hyperoxaluria Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- Figure 61: Europe Primary Hyperoxaluria Drug Revenue (2021-2032) & (US\$ Million)
- Figure 62: Europe Primary Hyperoxaluria Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- Figure 63: Asia-Pacific Primary Hyperoxaluria Drug Revenue (2021-2032) & (US\$ Million)
- Figure 64: Asia-Pacific Primary Hyperoxaluria Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- Figure 65: South America, Middle East and Africa Primary Hyperoxaluria Drug Revenue (2021-2032) & (US\$ Million)
- Figure 66: South America, Middle East and Africa Primary Hyperoxaluria Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- Figure 67: Primary Hyperoxaluria Drug Value Chain
- Figure 68: Manufacturing Cost Structure
- Figure 69: Primary Hyperoxaluria Drug Production Mode & Process
- Figure 70: Direct Comparison with Distribution Share
- Figure 71: Distributors Profiles
- Figure 72: Years Considered
- Figure 73: Research Process
- Figure 74: Key Executives Interviewed

